Creative Biolabs Enhances Site-specific Conjugation Services for Antibody-drug Conjugates Development

New York, June 30, 2019 Creative Biolabs, a renowned biotech company occupied in antibody design and modification, now enhances their site-specific conjugation services for antibody-drug conjugate (ADCs) development in order to offer a more comprehensive solution for global clients.

New York, United States – June 30, 2019 /MarketersMedia/ —

As a combination of chemotherapy and immunotherapy, antibody-drug conjugate provides a new way for numerous patients who suffering from various diseases, even cancers. A qualified ADC drug is based on the generation of a suitable antibody and subsequently the attachment of a cytotoxic drug to form the precision-guided munition, each of which requires a standard procedure, an excellent platform and timely support from reliable technicians. In Creative Biolabs, seasonable scientists with Ph.D. levels, who have spent over 10 years improving the exclusive site-specific conjugation services, are capable of customizing a suitable conjugation strategy for ADC engineering in terms of clients’ specific needs.

“Aiming at a narrower DAR, we have explored and adopted several methodologies to introduce specific and chemically versatile conjugation sites into the antibody sequences， such as incorporating Cysteine residues into defined sites on an antibody to create thiol-engineered antibody (EnCys-mAb) and conjugate payload drugs onto those Cysteine residues via thiol-based chemistry. And we take advantage of the self-splicing inteins and engineer intein-fusion antibodies, thereby achieving C-terminal specific antibody modification and yielding conjugates with DARs at 1 or 2,” said a scientist in Creative Biolabs.

“Meanwhile, for the sake of high-quality site-specific antibody-drug conjugations, we also apply several enzymatic or physical approaches by modifying the carbohydrate moiety via galactosidases and galactosyltransferases or photo-crosslinking indole-3-butyric acid containing linkers onto antibody nucleotide binding site. Engineered/non-engineered antibodies are conjugated to the drug-linker set designed and prepared in DrugLnk and purified by the liquid chromatography technology. Our ADCs are characterized for several basic biochemical parameters such as DAR, stability, conjugation site distribution.”

Site-specification conjugation plays an essential part of a successful ADC development project. Equipped with a professional team and an advanced ADC biotechnology, Creative Biolabs will be the best partner in creating customized ADCs. More information can be reached at https://www.creative-biolabs.com/adc/.

About
With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.

Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs Inc.
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Website: https://www.creative-biolabs.com/adc/

Source URL: https://marketersmedia.com/creative-biolabs-enhances-site-specific-conjugation-services-for-antibody-drug-conjugates-development/88891286

Source: MarketersMedia

Release ID: 88891286

Go Top